Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. is posited for a positive outlook due to its innovative bifunctional therapy, ficera, which targets both EGFR and TGF-β, underpinning its potential to capture approximately 30% of the eligible head and neck squamous cell carcinoma (HNSCC) market. The company's recent advancements in dosing strategies suggest a strong likelihood of securing regulatory approval, while clinical outcomes indicate that ficera could provide a significant improvement over the standard of care in third-line plus metastatic colorectal cancer (mCRC) due to its mechanism of action. Additionally, the combination of ficera with pembrolizumab potentially yields high objective response rates, further enhancing Bicara's position within the rapidly evolving oncology space.

Bears say

Bicara Therapeutics Inc. faces a challenging outlook due to underwhelming clinical results from its lead product, ficera, which has a probability of success of only 30% for head and neck squamous cell carcinoma (HNSCC). The company also lacks differentiated clinical data and may struggle against competitive drugs, potentially leading to reduced sales forecasts. Furthermore, with increasing immunity due to expanded HPV vaccinations, the incidence of HPV-attributable HNSCC is expected to decline, adversely affecting the market potential for Bicara's therapies.

BCAX has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 7 analysts, BCAX has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.